SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Okazaki K, Uchida K, Koyabu M, Miyoshi H, Takaoka M.Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease.J Gastroenterol2011;46:27788.
  • 2
    Uchida K, Masamune A, Shimosegawa T, Okazaki K.Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009.Int J Rheumatol2012;2012:358371.
  • 3
    Zen Y, Nakanuma Y.IgG4-related disease: a cross-sectional study of 114 cases.Am J Surg Pathol2011;34:18129.
  • 4
    Ebbo M, Daniel L, Pavic M, Seve P, Hamidou M, Andres E, et al.IgG4-related systemic disease: features and treatment response in a French cohort. Results of a multicenter registry.Medicine (Baltimore)2012;91:4956.
  • 5
    Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al.Consensus statement on the pathology of IgG4-related disease.Mod Pathol2012;25:118192.
  • 6
    Maire F, Le Baleur Y, Rebours V, Vullierme MP, Couvelard A, Voitot H, et al.Outcome of patients with type 1 or 2 autoimmune pancreatitis.Am J Gastroenterol2011;106:1516.
  • 7
    Kamisawa T, Egawa N, Inokuma S, Tsuruta K, Okamoto A, Kamata N, et al.Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy.Pancreas2003;27:2358.
  • 8
    Raissian Y, Nasr SH, Larsen CP, Colvin RB, Smyrk TC, Takahashi N, et al.Diagnosis of IgG4-related tubulointerstitial nephritis.J Am Soc Nephrol2011;22:134352.
  • 9
    Ebbo M, Grados A, Bernit E, Vely F, Boucraut J, Harle JR, et al.Pathologies associated with serum IgG4 elevation.Int J Rheumatol2012;2012:602809.
  • 10
    Yamamoto M, Tabeya T, Naishiro Y, Yajima H, Ishigami K, Shimizu Y, et al.Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases.Mod Rheumatol2012;22:41925.
  • 11
    Morel N, Rigolet A, Schleinitz N, Garnier A, Costedoat-Chalumeau N.Bilateral enlargement of the lacrimal glands from IgG4-related systemic disease [letter].Ann Intern Med2012;156:66970.
  • 12
    Shimizu Y, Yamamoto M, Naishiro Y, Sudoh G, Ishigami K, Yajima H, et al.Necessity of early intervention for IgG4-related disease: delayed treatment induces fibrosis progression.Rheumatology (Oxford)2013;52:67983.
  • 13
    Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al.Standard steroid treatment for autoimmune pancreatitis.Gut2009;58:15047.
  • 14
    Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al.Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis.Gut2012. E-pub ahead of print.
  • 15
    Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, Vucinic-Mihailovic V, Artiko V, Saranovic D, et al.The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis.J Nucl Med2012;53:15439.
  • 16
    Treglia G, Mattoli MV, Leccisotti L, Ferraccioli G, Giordano A.Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review.Clin Rheumatol2011;30:126575.
  • 17
    Sato M, Okumura T, Shioyama Y, Imura J.Extrapancreatic F-18 FDG accumulation in autoimmune pancreatitis.Ann Nucl Med2008;22:2159.
  • 18
    Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M.The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions.Eur J Nucl Med Mol Imaging2007;34:208895.
  • 19
    Matsubayashi H, Furukawa H, Maeda A, Matsunaga K, Kanemoto H, Uesaka K, et al.Usefulness of positron emission tomography in the evaluation of distribution and activity of systemic lesions associated with autoimmune pancreatitis.Pancreatology2009;9:6949.
  • 20
    Ozaki Y, Oguchi K, Hamano H, Arakura N, Muraki T, Kiyosawa K, et al.Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography.J Gastroenterol2008;43:14451.
  • 21
    Suga K, Kawakami Y, Hiyama A, Hori K, Takeuchi M.F-18 FDG PET-CT findings in Mikulicz disease and systemic involvement of IgG4-related lesions.Clin Nucl Med2009;34:1647.
  • 22
    Nguyen VX, De Petris G, Nguyen BD.Usefulness of PET/CT imaging in systemic IgG4-related sclerosing disease: a report of three cases.JOP2011;12:297305.
  • 23
    Nakajo M, Jinnouchi S, Noguchi M, Uozumi K, Tanabe H, Tateno R, et al.FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease.Clin Nucl Med2007;32:2825.
  • 24
    Nakatani K, Nakamoto Y, Togashi K.Utility of FDG PET/CT in IgG4-related systemic disease.Clin Radiol2012;67:297305.
  • 25
    Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al.Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011.Mod Rheumatol2012;22:2130.
  • 26
    Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al.FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging. Version 1.0.Eur J Nucl Med Mol Imaging2010;37:181200.
  • 27
    Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M.Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP.J Gastroenterol2010;45:4717.
  • 28
    Tomiyama T, Uchida K, Matsushita M, Ikeura T, Fukui T, Takaoka M, et al.Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis.J Gastroenterol2011;46:696704.
  • 29
    Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al.Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience.Gut2012. E-pub ahead of print.
  • 30
    Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH.Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.Medicine (Baltimore)2012;91:5766.
  • 31
    Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K, et al.Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease.Intern Med2011;50:6975.
  • 32
    Saegusa H, Momose M, Kawa S, Hamano H, Ochi Y, Takayama M, et al.Hilar and pancreatic gallium-67 accumulation is characteristic feature of autoimmune pancreatitis.Pancreas2003;27:205.
  • 33
    Vaglio A, Versari A, Fraternali A, Ferrozzi F, Salvarani C, Buzio C.18F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis.Arthritis Rheum2005;53:1225.
  • 34
    Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al.Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders.Ann Rheum Dis2009;68:13105.
  • 35
    Yamamoto M, Takahashi H, Ishigami K, Yajima H, Shimizu Y, Tabeya T, et al.Relapse patterns in IgG4-related disease [letter].Ann Rheum Dis2012;71:1755.
  • 36
    Detlefsen S, Zamboni G, Frulloni L, Feyerabend B, Braun F, Gerke O, et al.Clinical features and relapse rates after surgery in type 1 autoimmune pancreatitis differ from type 2: a study of 114 surgically treated European patients.Pancreatology2012;12:27683.
  • 37
    Nishina N, Kaneko Y, Kuwana M, Hanaoka H, Kameda H, Mikami S, et al.IgG4-related disease without overexpression of IgG4: pathogenesis implications.Case Rep Rheumatol2012;2012:754935.
  • 38
    Carruthers MN, Stone JH, Deshpande V, Khosroshahi A.Development of an IgG4-RD responder index.Int J Rheumatol2012;2012:259408.
  • 39
    Vaglio A, Greco P, Versari A, Filice A, Cobelli R, Manenti L, et al.Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent “scar”? A study using 18F-fluorodeoxyglucose positron emission tomography.Clin Exp Rheumatol2005;23:2314.
  • 40
    Shapiro KA, Bove RM, Volpicelli ER, Mallery RM, Stone JH.Relapsing course of immunoglobulin G4-related pachymeningitis.Neurology2012;79:6046.
  • 41
    Yamamoto M, Takahashi H, Tabeya T, Suzuki C, Naishiro Y, Ishigami K, et al.Risk of malignancies in IgG4-related disease.Mod Rheumatol2012;22:4148.